Metasyn joins forces with Daiichi
Contrast developer Metasyn has signed a $12 million agreementwith Daiichi Radioisotope Laboratories of Tokyo for Japanese developmentand marketing of MS-325, Metasyn's vascular MRI contrast agent.Under the agreement, Metasyn will receive $12 million in
Contrast developer Metasyn has signed a $12 million agreement
with Daiichi Radioisotope Laboratories of Tokyo for Japanese development
and marketing of MS-325, Metasyn's vascular MRI contrast agent.
Under the agreement, Metasyn will receive $12 million in license
fees, milestone payments, and an equity investment, in addition
to royalties on sales of the product. Daiichi will be responsible
for clinical development, registration, and commercialization
of MS-325 in Japan. Metasyn, of Cambridge, MA, will manufacture
MS-325 for Daiichi and will retain rights to the product outside
Japan. Metasyn expects to begin clinical trials of the agent in
the U.S. this year.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
